Led · Series A · Aug 2026

Remedium Bio is advancing a proprietary Prometheus™ platform designed to enable controlled, long-lasting expression of therapeutic proteins by harnessing adipocytes as a durable site for production. The platform aims to provide multi-year benefit with adjustable dosing following minimally invasive subcutaneous administration and to replace many subcutaneously administered protein therapies with single-injection, adjustable gene therapies. Its pipeline includes programs targeting endocrinology, immunology, neurology, and musculoskeletal diseases. The company recently completed an initial closing of a $10 million Series A led by LifeSpan Vision Ventures, with participation from Eli Lilly and Company and HKX Capital. Remedium is using the financing to advance lead programs, expand the platform, and prepare for first-in-human clinical studies. The announcement was issued from Norwalk, Connecticut.

Led · Seed · May 2026

Violet Therapeutics uses its proprietary CONNECT platform to map cellular interaction networks at scale and identify novel therapeutic targets implicated in neuroinflammation and neurodegeneration. Its lead program is a small-molecule candidate targeting EphB3, a receptor tyrosine kinase implicated in microglia–astrocyte signaling and synaptic loss. The company is preclinical-stage and plans IND-enabling studies for the EphB3 program, funded in part by the recently closed $4.75M seed extension. Violet was founded by Mass General Brigham Ventures with researchers from Brigham and Women’s Hospital and is based in Cambridge, MA. The company aims to build a pipeline of first-in-class CNS therapies that prevent synapse loss and restore synaptic function across neurodegenerative diseases.

Led · Seed · Feb 2026

Sift Biosciences is a preclinical immunotherapy company creating “T-cell booster” peptides that activate infection-trained memory T cells, aiming to overcome the low immunogenicity that limits many current cancer treatments. Its proprietary platform combines artificial intelligence, metagenomics, and high-throughput immune profiling to identify microbial analogs of tumor-associated epitopes capable of rapidly amplifying immune responses. The initial pipeline targets solid tumors such as microsatellite-stable colorectal and ovarian cancers, while parallel research explores selectively expanding regulatory T cells for autoimmune disease. Founded in 2024 as a UC Berkeley spin-out and headquartered in San Carlos, California, the team is led by CEO and co-founder Clare Lou, Ph.D. The company has raised $3.7 million in pre-seed capital to fund in-vivo proof-of-concept studies, expand its AI-powered discovery engine, and select lead oncology candidates. Early preclinical data suggest the potential for faster, more potent, and durable immune responses compared with existing approaches. Financially, the company is still pre-revenue and focused on advancing its research programs toward clinical validation.

Participated · Seed · Jan 2026

TECregen pioneers thymus regeneration with a pipeline of differentiated thymopoietic biologics designed to revitalize and expand thymic epithelial cells (TECs) and replenish T-cell populations. Its therapeutic approach targets conditions driven by impaired T-cell responses, aiming to boost immune recovery after transplantation or cytotoxic therapy, promote lifelong immune health, and improve immune surveillance against cancer. The platform also holds promise across broader immunology, oncology, and rare-disease indications. Fresh capital from a CHF 10 million seed financing provides the resources to advance preclinical programs toward first-in-human studies. The company has reinforced its leadership by appointing seasoned biotech executive Dr. Bo Rode Hansen as chairman to guide strategic growth. Backed by a syndicate of specialized life-science investors, TECregen is positioning itself at the forefront of immune-restoration therapeutics. No revenue or user metrics have been disclosed, as the company remains in the preclinical stage.

Participated · Series A · Jan 2025

Immunis is a clinical-stage biotechnology company developing stem cell‑derived, multi-active biologics using its multi-active secretome technology to deliver natural human immune modulators. Its lead investigational product, IMM01‑STEM, is being developed to address age-related muscle atrophy and metabolic dysfunction in elderly patients. A Phase 1/2a trial in nine elderly patients showed safety, tolerability and suggestive efficacy, including improvements in quality-of-life measures and gait speed. Preclinical studies in aged mouse models published in GeroScience and Aging Cell showed reversal of muscle atrophy, improved muscle function, enhanced metabolism and reduced body and liver fat. The company describes itself as the leading biotech with the most advanced stem cell‑derived multi-active biologic in human clinical trials. The recently closed financing will fund two Phase 2 clinical trials to further test IMM01‑STEM’s efficacy in targeted elderly populations. Immunis is a private biotech developing a novel immunomodulatory secretome product line (STEM) to address age- and disease-related immune decline. The STEM product line leverages stem cell technology to deliver all-natural, all-human immune modulators in their natural, relative physiological concentrations. Its lead secretome treatment, IMM01-STEM, is described as using natural immunomodulators with potent cytoskeletal remodeling properties. The company plans to use the new funding to support clinical assessment of IMM01-STEM in an FDA-awarded Phase 1/2a clinical trial targeting muscle atrophy. The trial targets muscle atrophy, a condition the article states is experienced by 100% of the population in age, disuse, and disease contexts. Immunis is based in Irvine, California.